US Patent

US7910610 — Methods of administering pirfenidone therapy

Method of Use · Assigned to Intermune Inc · Expires 2030-01-08 · 4y remaining

Vulnerability score 73/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects methods for administering pirfenidone therapy while avoiding adverse interactions with certain other medications.

USPTO Abstract

The present invention relates to methods involving avoiding adverse drug interactions with fluvoxamine and pirfenidone or other moderate to strong inhibitors of CYP enzymes.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-1604`	—
`U-2048`	—
`U-2048`	—
`U-2049`	—

Patent Metadata

Patent number: US7910610
Jurisdiction: US
Classification: Method of Use
Expires: 2030-01-08
Drug substance claim: No
Drug product claim: No
Assignee: Intermune Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.